Point Biopharma Global Inc Expected To Post A Loss Of 31 Cents A Share: Earnings Preview

POINT Biopharma Global

09/05/2023 16:02

* POINT Biopharma Global Inc  PNT.OQ   PNT.O  is expected
to show
no change in quarterly revenue when it reports  results on May
11 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for POINT Biopharma
Global
Inc is for a loss of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for POINT
Biopharma
Global Inc is $14​, above​ its last closing price of $8.13. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.26                        
 Sep. 30 2022  -0.27       -0.28      -0.26     Beat    7.9
 Jun. 30 2022  -0.21       -0.22      -0.27     Missed  -21.6​
 Mar. 31 2022  -0.19       -0.21      -0.18     Beat    14.3
 ​​Dec.        -0.22       -0.23      -0.16     Beat    31.9
 31 2021                                                
 Sep. 30 2021  -0.19       -0.19      -0.19     Met     -1.8​
 Jun. 30 2021  -0.11       -0.11      -0.15     Missed  -36.4
 This summary was machine generated May 9 at 15:02 GMT.  All
figures in US dollars  unless otherwise stated